# Lifestyle Plus the Drug

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/lifestyle-plus-the-drug

> Across 98,261 veterans with type 2 diabetes, taking a GLP-1 and keeping six to eight healthy habits was associated with 43% fewer cardiovascular events than three or fewer habits and no drug. The two figures people will compare cannot be compared.

## Key points

- GLP-1 plus 6–8 healthy habits: 43% fewer major cardiovascular events than 3 or fewer habits and no drug.
- You cannot rank 0.40 against 0.84: one compares extremes of a gradient, the other a yes/no.
- The two are not alternatives, which is the opposite of how the choice is usually framed.
- Observational, in veterans with type 2 diabetes, a population that skews older and male.

The tiresome argument about whether people should “just eat better instead” now has data from 98,261 veterans with type 2 diabetes followed across 632,543 person-years. Doing both was linked to fewer cardiovascular events than doing either. People taking a GLP-1 *and* keeping six to eight healthy habits had **43% fewer** major cardiovascular events than people with three or fewer habits and no drug.[1]

## What was measured

*Adjusted hazard ratios for major adverse cardiovascular events. Note that the comparison groups differ between rows.*

| Comparison | Hazard ratio |
| --- | --- |
| All eight low-risk lifestyle habits vs one or fewer | 0.40 (95% CI 0.30–0.54) |
| GLP-1 users vs non-users | 0.84 (95% CI 0.76–0.92) |
| **GLP-1 plus six to eight habits vs three or fewer habits and no GLP-1** | **0.57 (95% CI 0.46–0.71)** |

The authors’ conclusion is that combining lifestyle change with pharmacotherapy was associated with a greater reduction than either approach alone.[1]

## The comparison you cannot make from this table

It is tempting to set 0.40 against 0.84 and conclude lifestyle is roughly four times more powerful than the drug. The table cannot support that comparison, and it is the misreading this study will be used for.

> The rows are different contrasts. One compares the extremes of an eight-point gradient; the other compares taking a drug against not taking it.

“Eight habits versus one or fewer” contrasts the healthiest people in the dataset against the least healthy across a wide range of behaviors. “GLP-1 user versus non-user” is a single yes-or-no. Those produce numbers that cannot be ranked against each other, any more than you could compare the effect of “the top versus bottom of a scale” with “on versus off a switch”.

There is a second problem specific to lifestyle findings in observational data. Adhering to eight healthy habits is not randomly distributed. It correlates with income, housing, working hours, disability, and every other advantage that independently predicts cardiovascular outcomes. Adjustment reduces that confounding but does not remove it. Only randomization does, and lifestyle trials that count heart attacks rather than kilograms are rare; [one assigned people with heart disease to a Mediterranean or a low-fat diet](https://glpwatchdog.org/research/mediterranean-diet-the-outcome-trial) and followed them for seven years.

## What the finding does support

- **The two are not alternatives.** This is the useful part. Public debate usually frames them as a choice between one and the other.
- **Taking the drug does not make lifestyle irrelevant.** The authors conclude that the drug combined with the habits was associated with a greater reduction in risk than either on its own.
- **The drug is not a substitute for the habits, and the habits are not a reason to refuse the drug.** The data support both halves of that.
- **It is consistent with the randomized picture.** In a four-arm trial we covered in [exercise plus a GLP-1](https://glpwatchdog.org/research/exercise-plus-glp1-what-changes), the drug alone did nothing for physical fitness while exercise did, and the combination did most.

> **This is an observational study of veterans with type 2 diabetes**, so it establishes association rather than causation, and the population is not representative (predominantly older and male). Its direction is consistent with the rest of the evidence, which is why we cite it, but it is not a trial.

## Frequently asked questions

### Is lifestyle change better than taking a GLP-1?

You cannot tell from this study, and it is the misreading to avoid. The lifestyle figure compares the extremes of a wide gradient, people with eight healthy habits against people with one or fewer, while the drug figure compares taking it against not. Those are different kinds of comparison and cannot be ranked.

### Does doing both help more than either alone?

That is what the authors conclude, from an association rather than a trial. People taking a GLP-1 and keeping six to eight low-risk lifestyle habits had 43% fewer major cardiovascular events than people with three or fewer habits and no drug, and the authors read that as the combination being associated with a greater reduction than either approach on its own.

### Does taking the drug make diet and exercise pointless?

No. The authors conclude that the drug combined with healthy habits was associated with a greater reduction in cardiovascular risk than either approach alone, and a separate randomized trial found the drug alone produced no improvement in physical fitness while exercise did.

### How reliable is the lifestyle finding?

Less than it looks. Adhering to eight healthy habits correlates with income, housing, working hours and disability, and each of those independently predicts cardiovascular outcomes. Statistical adjustment reduces that problem without removing it.

### Who was studied?

98,261 people with type 2 diabetes and no previous heart attack, stroke or advanced kidney disease, in a Veterans Affairs population, followed across 632,543 person-years, during which 10,443 developed a major cardiovascular event. It is observational, and the population skews older and male, so it does not show whether the same holds for people without diabetes.

## References

1. Nguyen XT, Li Y, Czernichow S, et al. Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes. The Lancet Diabetes & Endocrinology. 2026. PMID: 41763234. https://pubmed.ncbi.nlm.nih.gov/41763234/

---

Cite as: GLP Watchdog, Nora Bissett, "Lifestyle Plus the Drug", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/lifestyle-plus-the-drug

Canonical HTML page: https://glpwatchdog.org/research/lifestyle-plus-the-drug

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
